Identification of potential COVID-19 treatment compounds which inhibit SARS Cov2 prototypic, Delta and Omicron variant infection.
Saved in:
| Title: | Identification of potential COVID-19 treatment compounds which inhibit SARS Cov2 prototypic, Delta and Omicron variant infection. |
|---|---|
| Authors: | Kumar P; Department of Microbiology and Immunology, University of Illinois-College of Medicine, Chicago, IL, USA., Mathayan M; Department of Microbiology and Immunology, University of Illinois-College of Medicine, Chicago, IL, USA., Smieszek SP; Vanda Pharmaceuticals Inc., Washington, DC, 20037, USA., Przychodzen BP; Vanda Pharmaceuticals Inc., Washington, DC, 20037, USA., Koprivica V; Vanda Pharmaceuticals Inc., Washington, DC, 20037, USA., Birznieks G; Vanda Pharmaceuticals Inc., Washington, DC, 20037, USA., Polymeropoulos MH; Vanda Pharmaceuticals Inc., Washington, DC, 20037, USA., Prabhakar BS; Department of Microbiology and Immunology, University of Illinois-College of Medicine, Chicago, IL, USA. Electronic address: bprabhak@uic.edu. |
| Source: | Virology [Virology] 2022 Jul; Vol. 572, pp. 64-71. Date of Electronic Publication: 2022 May 16. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Academic Press Country of Publication: United States NLM ID: 0110674 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-0341 (Electronic) Linking ISSN: 00426822 NLM ISO Abbreviation: Virology Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
